<![CDATA[Subcutaneous Amivantamab Receives FDA Priority Review in R/M HNSCC]]>

RegulatoryAmivantamabPositive

AI Analysis

Summary

Subcutaneous amivantamab received FDA Priority Review for recurrent/metastatic head and neck squamous cell carcinoma, supported by phase 1b/2 OrigAMI-4 trial data.

Clinical Trial Data

Phase

1b/2

Outcome Details

Subcutaneous formulation received FDA Priority Review

Importance:6/10

Sentiment:

0.60

FDA Priority ReviewSubcutaneous formulationHead and neck cancerRegulatoryAmivantamab

Read the original article

Published by Cancer Network on July 31, 2026 5:00 PM

Read Original